Phase II study of Dovitinib in recurrent glioblastoma

The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review

(2016) Thomas M. Atkinson et al.   SUPPORTIVE CARE IN CANCER

Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

(2016) Ace J. Hatch et al.   Cancer Medicine

The role of Myc and let-7a in glioblastoma, glucose metabolism and response to therapy

(2015) Gang Wang et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

A novel pathway of cellular activation mediated by antiphospholipid antibody-induced extracellular vesicles

(2015) M. Wu et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus

(2015) Y. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer

(2014) B. Escudier et al.   CLINICAL CANCER RESEARCH

miRNA microarray reveals specific expression in the peripheral blood of glioblastoma patients

(2014) LUN DONG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma

(2014) Rui Li et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas

(2014) Andrew D. Norden et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

(2013) E. Galanis et al.   CLINICAL CANCER RESEARCH

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

(2013) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)

(2013) Markus Hutterer et al.   NEURO-ONCOLOGY

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

(2013) Yingmiao Liu et al.   Cancer Medicine

Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas

(2012) Cuihua Yang et al.   INTERNATIONAL JOURNAL OF CANCER

The role of microRNAs in synaptic development and function

(2011) Rachel Corbin et al.   BMB Reports

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Let-7 microRNA inhibits the proliferation of human glioblastoma cells

(2010) Soon-Tae Lee et al.   JOURNAL OF NEURO-ONCOLOGY

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

(2009) N Murukesh et al.   BRITISH JOURNAL OF CANCER

The role of let-7 in cell differentiation and cancer

(2009) Benjamin Boyerinas et al.   ENDOCRINE-RELATED CANCER

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

The let-7 family of microRNAs

(2008) Sarah Roush et al.   TRENDS IN CELL BIOLOGY